Oncopeptides’ Pepaxto Needs New Study To Identify Population That Will Benefit, FDA Panel Says

Advisory committee votes 14-2 that melflufen’s benefit-risk profile is unfavorable in the current accelerated approval indication for fifth-line treatment of multiple myeloma; panel rejects sponsor’s attempt to rely on post hoc analyses to 'carve out' a subpopulation that, it asserts, is responsible for negative overall survival trend in OCEAN confirmatory trial.

Dim room
Pepaxto's near-term future in the US appears dim following a strongly negative advisory committee vote. • Source: Shutterstock

Oncopeptides AB should conduct a prospective, randomized trial to identify an appropriate patient population for Pepaxto (melphalan flufenamide, or melflufen) because the multiple myeloma drug’s benefit-risk profile in its current indication is not favorable, a US Food and Drug Administration panel said on 22 September.

More from US FDA Performance Tracker

More from Regulatory Trackers